Retina

Looking back at 2016's predictions of the future.

When it comes to treating retinal disease, VEGF isn’t the only game in town.

Heidelberg Engineering has started delivering the OCT-Angiography Module to SPECTRALIS® customers outside the United States. The OCT Angiography Module non-invasively produces detailed three-dimensional representations of the perfused retinal and choroidal vasculatures.

DME treatment and the impact it has on the macula – and the patient.

Have reports of NSAIDS preventing post-cataract macular edema been exaggerated?

A thinner retina could predict neurodegeneration in diabetes - and vice versa.

Could glucose metabolism be an alternative target for treating RP?

The Annual Meeting of the American Academy of Ophthalmology (AAO) took place mid-October in Chicago. As one of the most eventful and internationally acclaimed meetings in ophthalmology, its program offered an array of clinically relevant information and product innovations. Highlights from Heidelberg Engineering included the launch of the SPECTRALIS Glaucoma Module Premium Edition in the US and a preview of the OCT Angiography Module*.

Pegpleranib in combination with ranibizumab found to work better than ranibizumab alone.

A summary of the Topcon-sponsored satellite symposium held at Euretina, Copenhagen, September 2016.